Observational Serial Chart Review of Repatha® Use in European Subjects With Hyperlipidaemia
Observational Serial Chart Review of Repatha® Use in European Subjects With Hyperlipidaemia
Review of clinical characteristics of patients who are prescribed Repatha® and how their treatment is managed.
Inclusion Criteria:
Adults (>18 years) Provided informed consent Initiated on Repatha® at physician's discretion, after 1st August 2015 Received at least one dose of Repatha®
Exclusion Criteria:
Enrolled in an interventional study of PCSK9 inhibitor within 12 weeks prior to initiation of Repatha® Received commercially available PCSK9 inhibitor within 12 weeks prior to initiation of Repatha®
Markleeberg, 04416, Germany
Viersen-Dülken, 41751, Germany
Cona FE, 44124, Italy
Lido Di Camaiore LU, 55041, Italy
Torrette Di Ancona, 60126, Italy